RPL17 and non-small cell lung carcinoma: We retrospectively analyzed patients with advanced NSCLC who received anti-programmed cell death protein (PD)-1 antibody combined with RetroNectin activated cytokine-induced killer (R-CIK) cells after failure of at least two regimens from October 2015 to April 2018 in our department.